Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market index [3][6]. Core Insights - The company reported a revenue of 3.54 billion yuan for 2025, reflecting a year-on-year growth of 21.08%. However, the net profit attributable to shareholders decreased by 2.1% to 301 million yuan, with a significant drop in non-recurring net profit by 22.84% [1][6]. - The revenue growth is attributed to several factors: the global capacity expansion strategy, particularly in Vietnam, the optimization of product structure, and the strengthening of customer relationships through a broad marketing network [5][6]. - The company’s total assets increased by 32.99% year-on-year, driven by the expansion of its operational scale and increases in financial and fixed assets [5]. Financial Projections - Revenue projections for 2025-2027 are 3.54 billion, 3.81 billion, and 4.40 billion yuan, with growth rates of 21.08%, 7.51%, and 15.51% respectively. The net profit for the same period is projected to be 301 million, 351 million, and 450 million yuan, with growth rates of -2.1%, 16.73%, and 28.19% respectively [6][7]. - The price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are estimated at 22.46, 19.24, and 15.01 respectively, indicating a favorable valuation trend [6][7].
英科再生(688087):动态点评:收入高增,利润增速略有承压